Skip to main content
Aptabio Therapeutics Inc. logo

Aptabio Therapeutics Inc. — Investor Relations & Filings

Ticker · 293780 ISIN · KR7293780003 KO Manufacturing
Open in API
Filings indexed 209 across all filing types
Latest filing 2020-04-10 Major Shareholding Noti…
Country KR South Korea
Listing KO 293780

About Aptabio Therapeutics Inc.

https://aptabio.com/

Aptabio Therapeutics Inc. is a biopharmaceutical company dedicated to developing first-in-class drugs for intractable diseases with high unmet medical needs. The company's research is driven by proprietary platform technologies. One core platform focuses on regulating oxidative stress through selective NOX (NADPH oxidase) inhibitors, targeting the root causes of inflammation and fibrosis to treat diabetic complications, vascular diseases, and neurodegenerative disorders. A second platform centers on the regulation of cancer-associated fibroblasts (CAF) to overcome resistance and enhance the efficacy of immuno-oncology therapies for difficult-to-treat cancers. By leveraging these distinct approaches, Aptabio aims to discover and advance novel therapeutic candidates for challenging medical conditions.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea. This type of filing is required when an entity's shareholding in a company crosses specific thresholds (typically 5%). In the context of the provided categories, this falls under 'Major Shareholding Notification' (MRQ), which covers notifications of changes in significant share ownership levels.
2020-04-10 Korean
기타경영사항(특허권취득)(자율공시)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent for a blood cancer treatment by Aptabio. It details the patent name, content, patent holder, and utilization plan. Since this is a regulatory disclosure of a specific corporate event (patent acquisition) that does not fit into financial reporting, governance, or shareholder meeting categories, it falls under the general regulatory filing category.
2020-04-02 Korean
주식매수선택권행사
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory filing from Aptabio regarding the exercise of stock options (주식매수선택권행사). It details the number of shares exercised, the exercise price, the individuals involved (executives and employees), and the impact on the company's capital structure. Since this involves the issuance of new shares resulting from the exercise of stock options, it falls under the category of share issuance or capital changes.
2020-03-30 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of a General Meeting of Shareholders (정기주주총회결과). It details the approval of financial statements, dividend decisions, board appointments, and other resolutions passed during the meeting held on 2020-03-27. This falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2020-03-27 Korean
사업보고서 (2019.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for AptaBio Co., Ltd. for the fiscal year ending December 31, 2019. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. While it contains financial data, it is the formal audit report rather than a standalone 10-K (which is a US-specific regulatory filing) or a simple earnings release. Given the structure and content, it falls under the 'Audit Report' category. FY 2019
2020-03-27 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal regulatory filing titled 'Audit Report Submission' (감사보고서 제출) submitted to the Korea Exchange (KRX). It provides the audit opinion (unqualified/appropriate), key financial data (assets, liabilities, equity, profit/loss), and details regarding the external auditor. While it contains financial data, it is a specific regulatory disclosure of the audit results rather than a full Annual Report (10-K) or a simple announcement of report publication (RPA). Given the specific nature of audit opinion disclosures in the Korean market, it fits best under the Audit Report category. FY 2019
2020-03-19 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.